American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 492-502, March 2009

Effect of Antimicrobial Locks for Tunneled Hemodialysis Catheters on Bloodstream Infection and Bacterial Resistance: A Quality Improvement Report

  • Saib A. Abbas, MRCP

      Affiliations

    • Department of Renal Medicine, Middlemore Hospital, Counties-Manukau District Health Board, Manukau, New Zealand
  • ,
  • Imad A. Haloob, FRACP

      Affiliations

    • Department of Renal Medicine, Tauranga Hospital, Bay of Plenty District Health Board, Tauranga, New Zealand
  • ,
  • Susan L. Taylor, FRCPA

      Affiliations

    • Department of Clinical Microbiology, Middlemore Hospital, Counties-Manukau District Health Board, Manukau, New Zealand
  • ,
  • Elizabeth M. Curry, MBChB

      Affiliations

    • Department of Renal Medicine, Middlemore Hospital, Counties-Manukau District Health Board, Manukau, New Zealand
  • ,
  • Bruce B. King, FRACP

      Affiliations

    • Department of Renal Medicine, Nelson Hospital, Nelson Marlborough District Health Board, Nelson, New Zealand
  • ,
  • Walter M. Van der Merwe, FRACP

      Affiliations

    • Department of Renal Medicine, Whangarei Hospital, Northland District Health Board, Whangarei, New Zealand
  • ,
  • Mark R. Marshall, FRACP

      Affiliations

    • Department of Renal Medicine, Middlemore Hospital, Counties-Manukau District Health Board, Manukau, New Zealand
    • Corresponding Author InformationAddress correspondence to Mark R. Marshall, FRACP, Department of Renal Medicine, Middlemore Hospital, Private Bag 93311, Auckland, New Zealand

Received 5 April 2008; accepted 18 September 2008. published online 16 January 2009.

Background

Catheter-restricted antimicrobial lock (AML) use reduces catheter-associated bloodstream infection (CA-BSI) in clinical trial settings, but may not be as effective in clinical settings and may increase bacterial resistance.

Design

Quality improvement report analyzed using a cross-sectional time series (unbalanced panel) design.

Setting & Participants

The study cohort comprised all prevalent adults treated with hemodialysis through a tunneled catheter for any, but not necessarily all, of the time from January 1, 2003, to June 30, 2006, in Manukau City, New Zealand (135,346 catheter-days, 404 tunneled catheters, 320 patients).

Quality Improvement Plan

Catheter-restricted AMLs (heparin plus gentamicin) for all tunneled catheters from July 1, 2004.

Measures

Repeated observations of CA-BSI, hospitalization, tunneled catheter removal, and death from CA-BSI analyzed by using generalized estimating equations with a single level of clustering for each tunneled catheter and patterns of bacterial resistance analyzed by using simple descriptive statistics.

Results

AML use was associated with reductions in rates of CA-BSI and hospitalization for CA-BSI by 52% and 69% for patients with tunneled catheters locked continuously with AMLs since their insertion compared with those with tunneled catheters that were not, respectively. AML exposure also was associated with a trend to increased gentamicin resistance amongst coagulase-negative staphylococci isolates, a pattern similar to that observed for BSIs in our general hemodialysis population in which tunneled catheters were not the source of BSI, but different from that in the general non–end-stage renal disease population in the region.

Limitations

This is an uncontrolled observational study and cannot prove causality. The follow-up period of 18 months is longer than for other studies, but still too short to definitely answer whether AML use drives bacterial resistance.

Conclusions

A change to use of AMLs may improve clinical outcomes; however, additional study of associated bacterial resistance is needed before AML use becomes standard care.

Index Words: Hemodialysis, dialysis catheters, bacterial resistance, bloodstream infection, antimicrobial locks

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2008.09.019 on January 16, 2009.

PII: S0272-6386(08)01567-9

doi:10.1053/j.ajkd.2008.09.019

American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 492-502, March 2009